The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.

Autor:	Fjermeros K; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Ghannoum S; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway., Geisler SB; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Bhargava S; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway., Tahiri A; Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway., Klajic J; Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway., Lüders T; Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway., Fongård M; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway., Nawaz MS; Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.; Department of Health and Exercise, School of Health Sciences, Kristiania University College, Oslo, Norway., Bosnjak-Olsen T; Novartis, Medical Affairs, Oslo, Norway., Buvarp UE; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Rosenskiold AKJ; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Nguyen NT; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Sletbak TT; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Seyedzadeh M; Department of Radiology, Akershus University Hospital, Lørenskog, Norway., Selsås K; Department of Endocrine & Breast Surgery, Akershus University Hospital, Lørenskog, Norway., Porojnicu AC; Department of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway., Skjerven HK; Department of Breast & Endocrine Surgery, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway., Hovda T; Department of Radiology, Drammen Hospital, Vestre Viken Hospital Trust, Norway., Sahlberg KK; Department of Research & Innovation, Vestre Viken Hospital Trust, Drammen, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway., Torland LA; Department of Research & Innovation, Vestre Viken Hospital Trust, Drammen, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway., Lyngra M; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Hammarström CL; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Hönigsperger EB; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Noone JC; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Mathiassen S; Department of Pathology, Akershus University Hospital, Lørenskog, Norway., Hurtado A; Functional Genomics group & Molecular Pathology Unit, Centro de Investigación del Cáncer (CSIC-Universidad de Salamanca), Campus Universitario Miguel de Unamuno s/n. 37007, Salamanca, Spain., Goel S; Peter MacCallum Cancer Centre, Australia & The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Koff A; Program in Molecular Biology, Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY USA., Tekpli X; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway., Kristensen VN; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway., Geisler J; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (32), pp. 2457-2466. Date of Electronic Publication: 2024 Jul 29.
DOI:	10.1080/14796694.2024.2377531
Abstrakt:	Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment. Trial registration number: NCT05163106 (ClinicalTrials.gov).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu